← back to search

Jeffrey J. Pu

VA Boston Healthcare System · US
Area of research
Genetics · Hematology
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, and Complement system in diseases.
h-index
22
citations
2,904
works
124
NIH funding
primary concept
Medicine
email

Recent publications

ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults
Blood Advances 2026cited by 2position: middledoi
Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia
Frontiers in Immunology 2023cited by 42position: middledoi
Acute myeloid leukemia cells and MSC-derived exosomes inhibiting transformation in myelodysplastic syndrome
Discover Oncology 2023cited by 8position: middledoi
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Blood Advances 2022cited by 53position: middledoi
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Blood 2021cited by 70position: middledoi
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Journal of Hematology & Oncology 2021cited by 67position: middledoi
CD70‐targeting CAR‐T cells have potential activity against CD19‐negative B‐cell Lymphoma
Cancer Communications 2021cited by 32position: middledoi
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Blood 2020cited by 318position: middledoi
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Clinical Cancer Research 2020cited by 114position: middledoi
Alternative Polyadenylation: a new frontier in post transcriptional regulation
Biomarker Research 2020cited by 96position: lastdoi
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
Cancer Medicine 2020cited by 14position: middledoi
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
Haematologica 2018cited by 164position: middledoi
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
Blood 2016cited by 188position: middledoi
Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study
Blood 2015cited by 17position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Wenhai Deng · Wenzhou Medical University2 papers (2021–2023)Wen Lei · Ministry of Education of the People's Republic of China2 papers (2021–2023)Aibin Liang · Tongji University1 papers (2021–2021)Jing Christine Ye · The University of Texas MD Anderson Cancer Center1 papers (2021–2021)Yanhong Tan · Shanxi Medical University1 papers (2023–2023)Delong Liu · Westchester Medical Center1 papers (2021–2021)Fanggang Ren · Shanxi Medical University1 papers (2023–2023)Hong Zheng · Pennsylvania State University1 papers (2021–2021)Shanshan Guo · Ministry of Education of the People's Republic of China1 papers (2023–2023)Wei Ding · Jilin University1 papers (2021–2021)Xiuhua Chen · University of Florida1 papers (2023–2023)Lan Zhang · Ministry of Education1 papers (2020–2020)Hongwei Wang · Nanjing Medical University1 papers (2023–2023)Xiaoxia Wang · Qingdao University1 papers (2023–2023)Na Zhang · Zhejiang Sci-Tech University1 papers (2023–2023)Na Zhang · First Affiliated Hospital of Jiangxi Medical College1 papers (2020–2020)Shuo Li · Fudan University1 papers (2023–2023)Hongyu Zhang · Capital Medical University1 papers (2023–2023)Hongtao Liu · University of Wisconsin–Madison1 papers (2021–2021)Panpan Chen · Anhui Agricultural University1 papers (2021–2021)